Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HIV: early-phase trial registry
109 of 304 indexed HIV trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #27 of 28,707 conditions by registered trial count.
304 US clinical trials · 109 currently recruiting · #27 of 28,707 conditions by registered trial count
HIV: 304 US clinical trials tracked, 109 recruiting.
HIV is the subject of 304 registered US clinical trials on ClinicalTrials.gov, 109 of them currently open to new participants. 25 are in Phase 3-4 (later-stage) and 64 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 24 of these trials.
Enrollment posture brief
Registry condition hiv
OPEN 109 | RECR 36% | LATE 25 | EARLY 64 | RANK #27 | SPON 24
Volume-matched condition peers
Nearest open-share peer: Acute Respiratory Failure (36% recruiting · 14 trials)
HIV lists 109 open slots (36% of 304 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for HIV on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
HIV recruits in line with its size-band peers.
109 of 304 indexed trials (35.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of HIV trials is spread across many organizations.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 24 of 304 trials (7.9%). 115 distinct sponsors appear on at least one study for this condition label.
-
Typical HIV enrolment sits around 100 participants.
Median target enrolment is 100 among the 304 trials that report a genuine target (sentinel values excluded). 142 of those (46.7%) plan for fewer than 100 participants.
-
HIV research is mostly interventional.
252 interventional and 52 observational studies make up this index (82.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
304 total, page 3 of 7
Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV
University of Maryland, Baltimore
NCT06691243
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
Yale University
NCT07040592
Transcranial Magnetic Stimulation for Methamphetamine Use Disorder in PLWH
Gopalkumar Rakesh
NCT06830980
Proof-of-concept of a Behavioral Intervention to Improve the Cardiovascular Health of People Living With HIV
University of Washington
NCT07105007
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 1
Yale University
NCT06004830
HIV, Equity, and Addiction Training (HEAT) Program
University of Alabama at Birmingham
NCT06370481
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2
Yale University
NCT06006143
Open Trial of Trauma-focused Psychodynamic Psychotherapy for People Living With HIV and PTSD
Montefiore Medical Center
NCT05929911
Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV
University of Hawaii
NCT06935838
ED2PrEP - Patient Focused, Low-burden Strategies for PrEP Uptake Among Emergency Departments
Albert Einstein College of Medicine
NCT05588193
Testing a Novel Data-to-Suppression (D2S) Intervention Strategy in the Ryan White HIV/AIDS Program
City University of New York
NCT05140421
Prevalence and Predictors of Hepatic Steatosis in Persons Living With HIV
University of California, San Francisco
NCT04795219
Achieving Equity in Patient Outcome Reporting for Timely Assessments of Life With HIV and Substance Use
University of Chicago
NCT06682468
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
Washington University School of Medicine
NCT01790373
Nonalcoholic Fatty Liver Disease in HIV Database
Johns Hopkins University
NCT05023044
Parent-focused Intervention to Reduce HIV Risk in Gay and Bisexual Adolescents
George Washington University
NCT05852600
Adherence and Clinical Correlates in Persons With HIV on TAF
University of Colorado, Denver
NCT05335590
Selection of a Protective T Cell-based HIV-1/FIV Vaccine
University of Florida
NCT02389595
Physical Activity for PLWH and Unhealthy Drinking
Boston University
NCT05505942
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ViiV Healthcare
NCT05911360
PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04926922
Effectiveness of Zidovudine vs. Zidovudine Plus Alpha Interferon vs. Interferon for Treatment of HIV
National Institute of Allergy and Infectious Diseases (NIAID)
NCT01125228
The HIV, Adipose Tissue Immunology, and Metabolism Study
Vanderbilt University Medical Center
NCT04451980
Oral Dronabinol-HIV
Yale University
NCT06034314
Promoting Employment in Persons Living With HIV/AIDS
UConn Health
NCT03959826
Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)
Weill Medical College of Cornell University
NCT05382208
High-Intensity Exercise to Attenuate Limitations and Train Habits in Older Adults With HIV
University of Colorado, Denver
NCT04550676
Standing Tall (Yima Nkqo)
Brigham and Women's Hospital
NCT04568460
Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP
Midway Specialty Care Center
NCT06145854
Tell Me More ("Dime Mas")
University of Miami
NCT06063083
HOPE in Action Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients
Johns Hopkins University
NCT03734393
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
National Cancer Institute (NCI)
NCT00092222
Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection
University of California, San Francisco
NCT02656511
Using the Ending Self-Stigma Intervention to Reduce Internalized Stigma Among People Living With HIV Who Use Substances
Friends Research Institute
NCT05704764
Emtricitabine/Tenofovir Alafenamide Switch Study for Transgender Individuals for HIV Pre-exposure Prophylaxis
University of California, San Diego
NCT04616963
A Trial to Evaluate an HIV Envelope Trimer, N332-GT5 gp140, Adjuvanted With SMNP in Adult Participants Without HIV
National Institute of Allergy and Infectious Diseases (NIAID)
NCT06033209
A Phase 1 Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) and Core-g28v2 60mer mRNA Vaccine (mRNA-1644v2-Core)
International AIDS Vaccine Initiative
NCT05001373
Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs
Yale University
NCT06411223
Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.
National Institute of Allergy and Infectious Diseases (NIAID)
NCT06332339
Cannabis Effects on Antiretroviral Therapy Pharmacokinetics and Neurotoxicity
University of California, San Diego
NCT04800159
Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults
Boris Juelg, MD PhD
NCT04983030
Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05903339
Safety and Survival of Genetically Modified White Blood Cells in HIV-infected Twins The Gemini Study
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04799483
Predictive Analytics and Clinical Decision Support to Improve PrEP Prescribing
Harvard Pilgrim Health Care
NCT06805877
Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients
City of Hope Medical Center
NCT02500849
Using CBPR to Engage Hazardous Drinking Women in the HIV Prevention and Care Continuum
Johns Hopkins University
NCT04090723
CD4 CAR+ ZFN-modified T Cells in HIV Therapy
University of Pennsylvania
NCT03617198
Implementation of Collaborative Care for Depression in VA HIV Clinics
VA Office of Research and Development
NCT05901272
Computerized Substance Use and Depression Screening and Behavioral Treatment in HIV Primary Care
University of California, San Francisco
NCT03217058
Assisted Partner Services and HIVST in Western Kenya
University of Washington
NCT04774835
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 32 |
| Phase 2 | 32 |
| Phase 3 | 12 |
| Phase 4 | 13 |
Top Sponsors
Named interventions
Most-linked intervention names on HIV records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on HIV trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this HIV page
304 registered trials, 109 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 109 HIV trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most HIV trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This HIV condition card totals 304 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.